Sei Investments Co. Takes Position in Disc Medicine, Inc. $IRON

Sei Investments Co. bought a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 15,510 shares of the company’s stock, valued at approximately $992,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arizona State Retirement System grew its holdings in shares of Disc Medicine by 2.2% during the 4th quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after purchasing an additional 144 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Disc Medicine by 3.3% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after buying an additional 215 shares in the last quarter. AlphaCentric Advisors LLC increased its holdings in Disc Medicine by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after buying an additional 216 shares during the period. Kennedy Capital Management LLC raised its stake in shares of Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock valued at $740,000 after buying an additional 296 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Disc Medicine by 1.7% during the 3rd quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock worth $1,622,000 after acquiring an additional 400 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO John D. Quisel sold 33,000 shares of the stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $74.96, for a total value of $2,473,680.00. Following the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at $16,945,757.44. This represents a 12.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jonathan Yen-Wen Yu sold 9,700 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00. Following the completion of the transaction, the chief operating officer owned 54,324 shares in the company, valued at $3,947,181.84. This represents a 15.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 110,712 shares of company stock valued at $7,997,536 over the last ninety days. Insiders own 3.76% of the company’s stock.

Disc Medicine Price Performance

Disc Medicine stock opened at $80.59 on Thursday. The business’s 50-day simple moving average is $74.19 and its 200 day simple moving average is $69.87. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -12.25 and a beta of 1.00. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, research analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IRON has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wedbush reissued an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. HC Wainwright boosted their price target on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Morgan Stanley lifted their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $106.00.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.